- Home
- Incretin Management in Type 2 Diabetes
Incretin Management in Type 2 Diabetes
- MI/ACS
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Please Note
This content is not indented for UK HCPs
Support Statement
This programme is supported by an unrestricted educational grant by Novo Nordisk A/S. The scientific programme has not been influenced in any way by the sponsors.
Overview
In this educational hub ‘Incretin Management in Type 2 Diabetes’ the faculty present the importance of screening and early intensification for better glycaemic control and improved vascular and mortality outcomes in type 2 diabetes.
In this series of CME accredited videos and downloadable summaries, leading global experts will guide you through how the incretin system works, what happens to it in type 2 diabetes and how to optimise the use of incretin-based agents for better patient outcomes.
Disclosure
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session of ‘Incretin Management in Type 2 Diabetes’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Primary care physicians (PCPs)/ General Practitioners (GPs)
- Endocrinologists
- Diabetologists
- Nurses
Learning Objectives
Upon completion of this activity, participants will be able to:
- Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
- Identify underlying facets of clinical inertia in T2DM care
- Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
- Recall efficacy & the mode of action of various incretin-based treatments
- Adopt an early, intensive glucose-lowering strategy in appropriate individuals
- Select appropriate incretin treatment & dosing regimens according to patient profiles
- Identify individuals likely to gain cardiovascular benefit from GLP-1RAs
- Select appropriate actions following adverse events from incretin-based treatments
Module |
Title |
Duration |
Speakers |
---|---|---|---|
Session 1 | Diabetes pathophysiology and the 'ominous octet' | 10 minutes | Silvio Inzucchi |
Session 2 | The incretin system & incretin-targeting agents | 10 minutes | Silvio Inzucchi |
Session 3 | Therapeutic inertia in T2DM | 10 minutes | Kamlesh Khunti |
Session 4 | Early glycaemic control in T2DM | 10 minutes | Kamlesh Khunti |
Session 5 | The use of GLP-1 RAs in T2DM | 10 minutes | Sarah Davies |
Session 6 | Incretin-based drugs: What does the data say? | 10 minutes | Sarah Davies |
Session 7 | Incretin-based drugs: Mode of action/delivery & dosing schedule | 10 minutes | G Michael Felker |
Session 8 | Appropriate prescribing practices | 10 minutes | G Michael Felker |
Session 9 | Beyond glycaemic control: Cardiovascular benefits | 10 minutes | Steven B Feinstein |
Session 10 | Beyond glycaemic control: Weight control | 10 minutes | Steven B Feinstein |
Incretin-based drugs: Mode of action/delivery & dosing schedule
Duration: 10 minutes
Speakers: G Michael Felker
Course Director
Speaker
Speaker
Speaker
Speaker